Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-23-256865
Filing Date
2023-10-16
Accepted
2023-10-16 16:01:54
Documents
13
Period of Report
2023-10-05
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A d563868d8ka.htm   iXBRL 8-K/A 29608
2 EX-3.1 d563868dex31.htm EX-3.1 5972
  Complete submission text file 0001193125-23-256865.txt   166505

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA spro-20231005.xsd EX-101.SCH 2527
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE spro-20231005_lab.xml EX-101.LAB 18656
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE spro-20231005_pre.xml EX-101.PRE 11680
7 EXTRACTED XBRL INSTANCE DOCUMENT d563868d8ka_htm.xml XML 5251
Mailing Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139
Business Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139 857-242-1600
Spero Therapeutics, Inc. (Filer) CIK: 0001701108 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-38266 | Film No.: 231327360
SIC: 2834 Pharmaceutical Preparations